Association between the rs1800795G > C polymorphism in the promoter of interleukin-6 gene and bladder cancer

Research output: Contribution to journalArticle

Abstract

Interleukin-6 (IL-6) is an inflammatory cytokines that plays a role in the development of cancer. Several studies have examined the relationship between the IL-6 -174G>C polymorphism and bladder cancer, but these results are inconclusive. Therefore, we conducted a meta-analysis to explore the association between IL-6 -174G>C polymorphism and bladder cancer risk. A comprehensive literature search was performed to identify eligible studies regarding the IL-6 -174G>C polymorphism and bladder cancer. Effect sizes under fixed-and random-effects models were calculated using odds ratios (ORs) with 95% confidence intervals (CIs). Finally, five case-control studies were included in the subsequent analyses. In the fixed-effect analysis, significantly higher bladder cancer risks of 1.20 (95% CI = 1.07-1.36) and 1.30 (95% CI = 1.08-1.56) were found for the dominant model (C/C+ G/C vs. G/G) and recessive model (C/C vs. G/C+ G/G), respectively. Especially for the Asian population, significantly greater bladder cancer risks of 1.63 (95% CI = 1.32-2.00) and 1.54 (95% CI = 1.07-2.21) were observed for the dominant model (C/C+ G/C vs. G/G) and the recessive model (C/C vs. G/C+ G/G), respectively. Non-significantly increased risks of bladder cancer were observed for the dominant and recessive models under the random-effects analysis. The major findings of this meta-analysis suggest that IL-6 -174G>C polymorphism is significantly associated with bladder cancer risk in the Asian population. Further studies with a larger sample size are needed to validate the effects of IL-6 polymorphisms on bladder cancer risk.
Original languageEnglish
Pages (from-to)3598-3604
Number of pages7
JournalInternational Journal of Clinical and Experimental Pathology
Volume11
Issue number7
Publication statusPublished - 2018

Fingerprint

Urinary Bladder Neoplasms
Interleukin-6
Genes
Confidence Intervals
Meta-Analysis
Sample Size
Population
Case-Control Studies
Odds Ratio
Cytokines
Neoplasms

Keywords

  • Bladder cancer
  • interleukin
  • meta-analysis
  • polymorphism

Cite this

@article{85caca5ef5a74b29b36ae976988edad9,
title = "Association between the rs1800795G > C polymorphism in the promoter of interleukin-6 gene and bladder cancer",
abstract = "Interleukin-6 (IL-6) is an inflammatory cytokines that plays a role in the development of cancer. Several studies have examined the relationship between the IL-6 -174G>C polymorphism and bladder cancer, but these results are inconclusive. Therefore, we conducted a meta-analysis to explore the association between IL-6 -174G>C polymorphism and bladder cancer risk. A comprehensive literature search was performed to identify eligible studies regarding the IL-6 -174G>C polymorphism and bladder cancer. Effect sizes under fixed-and random-effects models were calculated using odds ratios (ORs) with 95{\%} confidence intervals (CIs). Finally, five case-control studies were included in the subsequent analyses. In the fixed-effect analysis, significantly higher bladder cancer risks of 1.20 (95{\%} CI = 1.07-1.36) and 1.30 (95{\%} CI = 1.08-1.56) were found for the dominant model (C/C+ G/C vs. G/G) and recessive model (C/C vs. G/C+ G/G), respectively. Especially for the Asian population, significantly greater bladder cancer risks of 1.63 (95{\%} CI = 1.32-2.00) and 1.54 (95{\%} CI = 1.07-2.21) were observed for the dominant model (C/C+ G/C vs. G/G) and the recessive model (C/C vs. G/C+ G/G), respectively. Non-significantly increased risks of bladder cancer were observed for the dominant and recessive models under the random-effects analysis. The major findings of this meta-analysis suggest that IL-6 -174G>C polymorphism is significantly associated with bladder cancer risk in the Asian population. Further studies with a larger sample size are needed to validate the effects of IL-6 polymorphisms on bladder cancer risk.",
keywords = "Bladder cancer, interleukin, meta-analysis, polymorphism",
author = "Yi-Te Chiang and Chen-Hsun Ho and Su-Wei Hu and Tse-Yen Yang and Chih-Wei Sung and Yuan-Hung Wang and Chia-Chang Wu",
year = "2018",
language = "English",
volume = "11",
pages = "3598--3604",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "E-CENTURY PUBLISHING CORP",
number = "7",

}

TY - JOUR

T1 - Association between the rs1800795G > C polymorphism in the promoter of interleukin-6 gene and bladder cancer

AU - Chiang, Yi-Te

AU - Ho, Chen-Hsun

AU - Hu, Su-Wei

AU - Yang, Tse-Yen

AU - Sung, Chih-Wei

AU - Wang, Yuan-Hung

AU - Wu, Chia-Chang

PY - 2018

Y1 - 2018

N2 - Interleukin-6 (IL-6) is an inflammatory cytokines that plays a role in the development of cancer. Several studies have examined the relationship between the IL-6 -174G>C polymorphism and bladder cancer, but these results are inconclusive. Therefore, we conducted a meta-analysis to explore the association between IL-6 -174G>C polymorphism and bladder cancer risk. A comprehensive literature search was performed to identify eligible studies regarding the IL-6 -174G>C polymorphism and bladder cancer. Effect sizes under fixed-and random-effects models were calculated using odds ratios (ORs) with 95% confidence intervals (CIs). Finally, five case-control studies were included in the subsequent analyses. In the fixed-effect analysis, significantly higher bladder cancer risks of 1.20 (95% CI = 1.07-1.36) and 1.30 (95% CI = 1.08-1.56) were found for the dominant model (C/C+ G/C vs. G/G) and recessive model (C/C vs. G/C+ G/G), respectively. Especially for the Asian population, significantly greater bladder cancer risks of 1.63 (95% CI = 1.32-2.00) and 1.54 (95% CI = 1.07-2.21) were observed for the dominant model (C/C+ G/C vs. G/G) and the recessive model (C/C vs. G/C+ G/G), respectively. Non-significantly increased risks of bladder cancer were observed for the dominant and recessive models under the random-effects analysis. The major findings of this meta-analysis suggest that IL-6 -174G>C polymorphism is significantly associated with bladder cancer risk in the Asian population. Further studies with a larger sample size are needed to validate the effects of IL-6 polymorphisms on bladder cancer risk.

AB - Interleukin-6 (IL-6) is an inflammatory cytokines that plays a role in the development of cancer. Several studies have examined the relationship between the IL-6 -174G>C polymorphism and bladder cancer, but these results are inconclusive. Therefore, we conducted a meta-analysis to explore the association between IL-6 -174G>C polymorphism and bladder cancer risk. A comprehensive literature search was performed to identify eligible studies regarding the IL-6 -174G>C polymorphism and bladder cancer. Effect sizes under fixed-and random-effects models were calculated using odds ratios (ORs) with 95% confidence intervals (CIs). Finally, five case-control studies were included in the subsequent analyses. In the fixed-effect analysis, significantly higher bladder cancer risks of 1.20 (95% CI = 1.07-1.36) and 1.30 (95% CI = 1.08-1.56) were found for the dominant model (C/C+ G/C vs. G/G) and recessive model (C/C vs. G/C+ G/G), respectively. Especially for the Asian population, significantly greater bladder cancer risks of 1.63 (95% CI = 1.32-2.00) and 1.54 (95% CI = 1.07-2.21) were observed for the dominant model (C/C+ G/C vs. G/G) and the recessive model (C/C vs. G/C+ G/G), respectively. Non-significantly increased risks of bladder cancer were observed for the dominant and recessive models under the random-effects analysis. The major findings of this meta-analysis suggest that IL-6 -174G>C polymorphism is significantly associated with bladder cancer risk in the Asian population. Further studies with a larger sample size are needed to validate the effects of IL-6 polymorphisms on bladder cancer risk.

KW - Bladder cancer

KW - interleukin

KW - meta-analysis

KW - polymorphism

M3 - Article

VL - 11

SP - 3598

EP - 3604

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 7

ER -